OLBA HEALTHCARE (2689) Q3 2025 earnings summary

Executive summary

• Net sales for the nine months ended March 31, 2025, increased by 3.4% year-over-year to ¥92,480 million.

• Operating profit declined by 23.3% year-over-year to ¥1,293 million.

• Profit attributable to owners of parent decreased by 16.4% year-over-year to ¥932 million.

• Comprehensive income fell by 19.1% year-over-year to ¥914 million.

Financial highlights

• Gross profit rose to ¥10,318 million from ¥10,184 million year-over-year.

• Selling, general and administrative expenses increased to ¥9,024 million from ¥8,497 million year-over-year.

• Basic earnings per share for the nine months was ¥157.48, down from ¥186.64 year-over-year.

• Total assets as of March 31, 2025, were ¥47,016 million, up from ¥43,237 million as of June 30, 2024.

• Equity ratio stood at 25.0% as of March 31, 2025.

Outlook and guidance

• Full-year net sales forecast for fiscal year ending June 30, 2025, is ¥123,726 million, up 4.4% year-over-year.

• Operating profit is projected at ¥2,270 million, a 1.9% increase year-over-year.

• Profit attributable to owners of parent is forecast at ¥1,465 million, down 2.4% year-over-year.

• Basic earnings per share for the full year is expected to be ¥247.65.